Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Açın
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0,21%
1.091,51
-2,30
-0,21%
—1.093,811.096,521.100,221.091,51——
SIXC
Communications
SIXC
Communications
SIXC
+0,22%
610,11
+1,34
+0,22%
—608,77608,77612,97608,77——
SIXE
Energy
SIXE
Energy
SIXE
-1,34%
1.237,98
-16,83
-1,34%
—1.254,811.253,011.253,871.226,33——
SIXI
Industrials
SIXI
Industrials
SIXI
-0,93%
1.744,71
-16,40
-0,93%
—1.761,111.764,271.766,881.744,71——
SIXM
Financials
SIXM
Financials
SIXM
-0,37%
640,18
-2,40
-0,37%
—642,58644,87648,48640,18——
SIXR
Staples
SIXR
Staples
SIXR
-0,18%
849,58
-1,55
-0,18%
—851,13855,66858,75845,56——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0,23%
217,48
-0,50
-0,23%
—217,98217,98218,65216,88——
SIXT
Technology
SIXT
Technology
SIXT
+1,52%
3.260,69
+48,86
+1,52%
—3.211,833.227,213.268,383.226,55——
SIXU
Utilities
SIXU
Utilities
SIXU
-0,69%
942,45
-6,53
-0,69%
—948,98948,58957,83941,97——
SIXV
Health care
SIXV
Health care
SIXV
-0,52%
1.466,80
-7,72
-0,52%
—1.474,521.479,031.481,041.466,80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0,22%
2.397,50
+5,38
+0,22%
—2.392,122.396,952.421,222.382,32——
LXRX:NASDAQ
Lexicon Pharmaceuticals Inc
1,63 US$
+1,24%
(+0,020) 1D
1,64 US$
+0,40% (+0,0065)
After hours
Closed: 1 may, 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LXRX...
Açın
1,59 US$
High
1,66 US$
Low
1,58 US$
Mkt. cap
690,60 mln
Avg. vol.
2,32 mln
Volume
1,40 mln
52-wk high
1,95 US$
52-wk low
0,51 US$
EPS
-0,14 US$
Beta
1,36
Shares outstanding
423,68 mln
No. of employees
81
News stories
From sources across the web
Profile
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its patented mouse gene knockout technology and extensive in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology. The company's clinical drug candidates include sotagliflozin for the treatment of type 2 diabetes; LX1033 for the treatment of irritable bowel syndrome and other gastrointestinal disorders; telotristat ethyl for the treatment of the symptoms associated with carcinoid syndrome; and LX2931 for the treatment of autoimmune diseases, such as rheumatoid arthritis. Wikipedia
About Lexicon Pharmaceuticals Inc
CEOLonnel Coats
Employees81
Founded1995
Headquarters-
SectorPharmaceutical industry
Websitelexpharma.com
Last report
5 mar 2026
Fiscal Period
Q4 2025
Normalized EPS / Estimate
-0,04/ (-0,07 est.)USD
+43,65%beat
Revenue / Estimate
5,49 mln/ (3,14 mln est.)USD
+74,85%beat
Fiscal Q4 2025 earnings call
Waiting for the earnings call
At a glanceInsights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
mar 2025
iyn 2025
sen 2025
dek 2025
Revenue
1,26 mln
28,87 mln
14,18 mln
5,49 mln
Cost of goods sold
1,60 mln
1,65 mln
18,77 mln
-43,32 mln
Cost of revenue
1,60 mln
1,65 mln
18,77 mln
-43,32 mln
Research and development expenses
13,73 mln
14,13 mln
-
54,83 mln
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
11,61 mln
9,35 mln
7,60 mln
8,76 mln
Operating expense
25,34 mln
23,48 mln
7,60 mln
63,59 mln
Total operating expenses
26,94 mln
25,13 mln
26,37 mln
20,27 mln
Operating income
-25,68 mln
3,74 mln
-12,19 mln
-14,78 mln
Other non operating income
-
-
-
-
EBT including unusual items
-25,30 mln
3,25 mln
-12,77 mln
-15,53 mln
EBT excluding unusual items
-25,30 mln
3,25 mln
-12,77 mln
-15,53 mln
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-25,30 mln
3,25 mln
-12,77 mln
-15,53 mln
Net profit margin
-2.004,36%
11,27%
-90,04%
-282,72%
Earnings per share
-0,07
0,01
-0,04
-0,04
Interest and investment income
2,22 mln
1,83 mln
1,57 mln
1,28 mln
Interest expense
-1,84 mln
-2,32 mln
-2,16 mln
-2,03 mln
Net interest expenses
384,00K
-484,00K
-582,00K
-750,00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-25,50 mln
3,91 mln
-12,04 mln
-14,66 mln
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer